Article
Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:
All News
Article
Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage.
In this compilation from the past week we talk about
- HIV and arthritis
- Hyperuricemia in PsA
- An odd kind of dermatomyositis
Article
The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology.
Article
Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
Article
Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve
Article
Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.
Article
The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
Article
A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.
Remdesivir
Mrinalini Dey
Tweet
Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadacitinib #JAKinhibitor
-HZ events more common in patients taking 30mg vs 15mg
-HZ more common in UPA vs those taking ADA+MTX & MTX
Abs#2002 #ACR20 @RheumNow
https://t.co/tQ03wBueW5
Olga Petryna
Tweet
@RheumNow #ACR20 abs1151 screening for inflammatory hyperferritinemia may be feasible but requires additional info: inflammatory huperferritinemia more likely to correlate with ⬆️IL18, AST&thrombocytosis while high CRP+ferritin more often seen in infectious etiology https://t.co/wiFPXepxpz
Mrinalini Dey
Tweet
Congrats @sdlcrodriguez on a great presentation!
Abs#1465: Combined #vaccination scheme leads to decreased incidence of Strep pneumoniae #infection in #rheumatoidarthritis patients taking b/tsDMARD.
#ACR20 @RheumNow
https://t.co/EwIj0PYbgI https://t.co/cqg8xtcB48
Mrinalini Dey
Tweet
It was a joy to discuss #infection in #rheumatic diseases, one of my favourite subspecialties, with @drjamesgalloway @KCLImmunoMicro.
Hear his reflections on #COVID19 and highlights from the many great infection-related abstracts at #ACR20. @RheumNow
https://t.co/KQ1NuKrQOI
Peter Nash
Tweet
Autoimmune Disease Outcomes of Women with Breast Implants: A Population-Based Study https://t.co/Z6R8zRezfN #breastimplants #IMID an old chestnut
Mrinalini Dey
Tweet
Time-trend analysis in hospitalised #infection in #lupus
-Incr. rate of hospitalised infections over time
-#Sepsis surpassed #pneumonia as most common hospitalised infection in 2011-12; twice as many sepsis vs pneumonia by 2015-16
Abs#0980 #ACR20 @RheumNow
https://t.co/M8xbMDFUTS https://t.co/ShogvxbhzN
Dr. Antoni Chan
Tweet
Wonderful Philip Hench Memorial Lecture from Prof Gerd Bursmester on the development of biologics in rheumatology from infections, the magic bullet, serendipity, perseverance, research to the present day @RheumNow #ACR20 #3S007 https://t.co/9H1AmZLTpJ
sheila
Tweet
For patients with #rheumatic disease, what test do you request in the work-up for Latent TB infection? @RheumNow #ACR20
Mrinalini Dey
Tweet
Patients with ARDs have incr. susceptibility to #infection. Real-world study shows suboptimal #influenza, #pneumococcal & #herpeszoster #vaccination coverage in these patients. Important to consider strategies to improve uptake.
Abs#0541 #ACR20 @RheumNow
https://t.co/GAapkzILvW
Meral K. El Ramahi, MD
Tweet
Infectious disease physician, Dr. Eric Rubin, kicks off the ACR keynote address by reminding us that there are real alliances between Infectious Disease doctors and Rheumatologists in that inflammation can cause damage during infection! #ACR20 @RheumNow https://t.co/pcOS1HbfX7
Meral K. El Ramahi, MD
Tweet
Determining safety of a vaccine requires NUMBERS (more subjects to detect rare, serious side effects) and TIME (longer trials to be able to detect more delayed side effects) per Dr. Eric Rubin’s (ID physician’s) keynote address at #ACR20 @RheumNow
Mrinalini Dey
Tweet
Delighted to be reporting for @RheumNow at #ACR20!
Here, I review the last year in #infection in #rheumaticdiseases (it’s been a busy one!) and highlight just a few of the abstracts on infections (incl #COVID19), #vaccination and #immunogenicity. Enjoy!
https://t.co/x1pzyOICAF
